Introduction: People with HIV are at higher risk of lung cancer; however, there is limited research on attitudes, barriers, and facilitators to lung cancer screening in people with HIV. The objective of this study was to understand the perspectives on lung cancer screening among people with HIV and their providers.
Methods: Surveys of people with HIV and HIV-care providers were complemented by qualitative focus groups and interviews designed to understand the determinants of lung cancer screening in people with HIV. Participants were recruited through an academic HIV clinic in Seattle, WA. Qualitative guides were developed by integrating the Consolidated Framework for Implementation Research and the Tailored Implementation of Chronic Diseases checklist. Themes that emerged from thematic analyses of qualitative data were compared with surveys in joint displays. All study components were conducted between 2021 and 2022.
Results: Sixty-four people with HIV completed surveys, and 43 participated in focus groups. Eleven providers completed surveys, and 10 were interviewed for the study. Themes from joint displays show overall enthusiasm for lung cancer screening among people with HIV and their providers, particularly with a tailored and evidence-based approach. Facilitators in this population may include longstanding engagement with providers and health systems and an emphasis on survivorship through preventive healthcare interventions. People with HIV may also face barriers acknowledged by providers, including a high level of medical comorbidities and competing issues such as substance abuse, mental health concerns, and economic instability.
Conclusions: This study reveals that people with HIV and their providers have overall enthusiasm toward screening. However, tailored interventions may be needed to overcome specific barriers, including complex decision making in the setting of medical comorbidity and patient competing issues.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524954 | PMC |
http://dx.doi.org/10.1016/j.amepre.2023.05.001 | DOI Listing |
Int J STD AIDS
January 2025
Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Background: (MG) is responsible for non-gonococcal urethritis. Our aim is to describe MG positivity rate and incidence in specific populations.
Methods: Retrospective, surveillance study included all samples collected from 2018 to 2022.
J Infect Dev Ctries
December 2024
Department of Neurosurgery, The third affiliated hospital, Sun Yat-Sen University, Guangzhou, China.
Introduction: Cryptococcal meningitis (CM) combined with intracranial hypertension is associated with a poor prognosis. This study aimed to investigate the therapeutic efficacy and prognostic factors of ventriculoperitoneal (VP) shunt in non-human immunodeficiency virus (HIV) CM patients with intracranial hypertension.
Methodology: A total of 136 non-HIV CM patients with intracranial hypertension treated in our hospital from July 2010 to December 2019 were retrospectively included.
J Infect Dev Ctries
December 2024
Department of Paediatrics, University of Calabar, Calabar, Cross River State, Nigeria.
Introduction: Globally, approximately 2.7 million and 2.3 million people living with HIV are co-infected with hepatitis B and C virus, respectively.
View Article and Find Full Text PDFAIDS
January 2025
Center for Biomedical Modeling, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, CA.
Objectives: To predict the burden of HIV in the United States (US) nationally and by region, transmission type, and race/ethnicity through 2030.
Methods: Using publicly available data from the CDC NCHHSTP AtlasPlus dashboard, we generated 11-year prospective forecasts of incident HIV diagnoses nationally and by region (South, non-South), race/ethnicity (White, Hispanic/Latino, Black/African American), and transmission type (Injection-Drug Use, Male-to-Male Sexual Contact (MMSC), and Heterosexual Contact (HSC)). We employed weighted (W) and unweighted (UW) n-sub-epidemic ensemble models, calibrated using 12 years of historical data (2008-2019), and forecasted trends for 2020-2030.
AIDS Behav
January 2025
Department of Health, Behavior and Society , Bloomberg School of Public Health, Johns Hopkins University, 624 N. Broadway, Hampton House 184, Baltimore, MD, 21205, USA.
This study aimed to examine shifts in the cost-savings threshold of a rural syringe services program (SSP) that resulted in the 12-months following the identification of the COVID-19 pandemic. We compared SSP operational costs during the 12-months immediately before and after identification of the COVID-19 pandemic using administrative data from the Cabell-Huntington Harm Reduction Program (CHHRP), which is operated by the Cabell-Huntington Health Department in West Virginia. Data included monthly counts of client encounters, sterile syringe distribution, and HIV testing.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!